Mucosal genomics implicate lymphocyte activation and lipid metabolism in refractory environmental enteric dysfunction

Najeeha Talat Iqbal  
*Aga Khan University*, najeeha.iqbal@aku.edu

Najeeb Rahman  
*Aga Khan University*, najeeb.rahman@aku.edu

Kamran Sadiq  
*Aga Khan University*, kamran.sadiq@aku.edu

Zubair Ahmad  
*Aga Khan University*, zubair.ahmad@aku.edu

Romana Idress  
*Aga Khan University*, romana.idress@aku.edu

*See next page for additional authors*

Follow this and additional works at: [https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr](https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr)

Part of the Gastroenterology Commons, Genomics Commons, Maternal and Child Health Commons, Nutritional and Metabolic Diseases Commons, and the Pediatrics Commons

**Recommended Citation**

*Available at:* [https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/987](https://ecommons.aku.edu/pakistan_fhs_mc_women_childhealth_paediatr/987)
Mucosal Genomics Implicate Lymphocyte Activation and Lipid Metabolism in Refractory Environmental Enteric Dysfunction


1Department of Pediatrics, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, Ohio; 2Department of Pediatrics, Sheba Medical Center, Tel-HaShomer, affiliated with the Tel-Aviv University, Israel; 3Department of Pediatrics and Child Health, Aga Khan University, Karachi, Pakistan; 4Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan; 5Department of Computer Science, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Engineering, Cincinnati, Ohio; 6Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia; 7Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan; and 8Department of Pediatrics, University of Virginia, Charlottesville, Virginia

BACKGROUND & AIMS: Environmental enteric dysfunction (EED) limits the Sustainable Development Goals of improved childhood growth and survival. We applied mucosal genomics to advance our understanding of EED. METHODS: The Study of Environmental Enteropathy and Malnutrition (SEEM) followed 416 children from birth to 24 months in a rural district in Pakistan. Biomarkers were measured at 9 months and tested for association with growth at 24 months. The duodenal methylome and transcriptome were determined in 52 undernourished SEEM participants and 42 North American controls and patients with celiac disease. RESULTS: After accounting for growth at study entry, circulating IGF-1 and ferritin predicted linear growth, whereas leptin correlated with future weight gain. The EED transcriptome exhibited suppression of antioxidant, detoxification, and lipid metabolism genes, and induction of anti-microbial response, interferon, and lymphocyte activation genes. Relative to celiac disease, suppression of antioxidant and detoxification genes and induction of antimicrobial response genes were EED-specific. At the epigenetic level, EED showed hyper-methylation of epithelial metabolism and barrier function genes, and hypo-methylation of immune response and cell proliferation genes. Duodenal coexpression modules showed association between lymphocyte proliferation and epithelial metabolic genes and histologic severity, fecal energy loss, and wasting (weight-for-length/height Z < -2.0). Leptin was associated with expression of epithelial carbohydrate metabolism and stem cell renewal genes. Immune response genes were attenuated by giardia colonization. CONCLUSIONS: Children with reduced circulating IGF-1 are more likely to experience stunting. Leptin and a gene signature for lymphocyte activation and dysregulated lipid metabolism are implicated in wasting, suggesting new approaches for EED refractory to nutritional intervention.

ClinicalTrials.gov, Number: NCT03588013.
Enteropathy in early childhood can have irreversible adverse effects on both growth and cognitive development. Environmental enteric dysfunction (EED) and celiac disease are prevalent enteropathies in this age group. Most previous studies of EED have used noninvasive stool, blood, and urine biomarkers because endoscopy is less commonly performed in the affected low-resource regions. Causative factors for EED in the diseased gut tissue have, therefore, remained incompletely defined. Previous work from Gambia using duodenal biopsy immunohistochemistry demonstrated a chronic T-cell–mediated enteropathy linked to malnutrition. In Bangladesh, recent work has defined specific EED duodenal microbiota associated with stunting, and transmission of histologic changes and weight loss to germ-free mice. Epigenetically, undernourished cohorts from Bangladesh captured differential histone methylation in peripheral blood, and from Jamaica and Malawi characterized differential DNA methylation (DNAm) of buccal mucosa samples, supporting epigenetic changes in inflammatory and lipid metabolism pathways in this population. However, epigenetic and transcriptional drivers of EED pathogenesis in the affected small intestine and longitudinal biomarkers to predict growth have not yet been defined.

To better characterize the longitudinal development of EED and growth failure during early childhood and to define key gut factors in children with severe EED refractory to nutritional intervention, we established the SEEM Pakistan cohort (Study of Environmental Enteropathy and Malnutrition). SEEM is an inception cohort following 416 at-risk children from birth up to 24 months of age. SEEM aimed to define longitudinal growth trajectories during the first 2 years of life and identify severe cases unresponsive to nutritional intervention that require endoscopic evaluation, define EED pathogenesis using histology, transcriptome, and epigenome (methylome) of duodenal biopsy specimens, and use data including noninvasive biomarkers collected up to 9 months of age to predict growth at 24 months.

Methods

Study Design

SEEM is an Aga Khan University (AKU) prospective cohort study that enrolled children at birth in Matari, Pakistan between 2016 and 2019 undergoing evaluation for EED and growth up to 24 months of age. The SEEM cohort consisted of 416 children (365 malnourished cases and 51 well-nourished healthy controls) with a median enrollment time of 5 days after birth. Anthropometry data were collected monthly, and participants received nutritional education. Child length was measured from birth to 24 months, and we refer to length/height throughout. Blood, urine, and fecal samples were collected at 9 months of age. Nutritional intervention according to Pakistan’s Community Management of Acute Malnutrition protocol using high-calorie AchaMum therapeutic food and close monitoring was offered to 189 cases with wasting (weight-for-length/height score [WHZ] < -2) at age 9–10 months up to the age of 12 months (Supplementary Figure 1). Esophagogastroduodenoscopy was performed as part of the clinical workup for 63 children with EED who did not respond
to the nutritional intervention. Histology was evaluated centrally at AKU by 2 pathologists by a consensus assessment. One research duodenal biopsy specimen for molecular profiling was obtained from each of the 57 participants, and RNA for transcriptomics was available for 52. Due to ethical considerations and lack of clinical indications to perform endoscopy on well-nourished Materi controls, biopsies from this population were not included. A prior study from Gambia demonstrated the utility of including healthy pediatric controls from the United Kingdom in defining pathogenic mechanisms in EED.4 We, therefore, enrolled 25 controls and 17 celiac disease subjects at the Cincinnati Children’s Hospital Medical Center. Controls were subjects who were investigated for digestive symptoms but had normal endoscopic and histologic findings. Celiac disease diagnosis was based on previously described algorithms including tissue transglutaminase auto-antibodies and characteristic histologic features. Supplementary Figure 1 illustrates the cases and controls for the transcriptomics analysis, and for the biomarker analysis. Each site’s Institutional Review Board approved the protocol and safety monitoring plan. Informed consent/assent was obtained for each participant.

Outcomes

SEEM was designed to understand the pathophysiology, growth predictors, and potential management strategies of EED. The primary outcome was length/height-for-age z score (HAZ), as a measure of stunting, at 24 months of age. The secondary outcomes were WHZ, as a measure of wasting, and weight-for-age z score (WAZ), as a measure of underweight at 24 months, and to define genes and pathways linked to EED pathogenesis.

Messenger RNAseq, Methylation Array, and Bioinformatic Analyses

Detailed messenger RNA (mRNAseq), methylation array, and bioinformatic methods are provided in the Supplementary Methods. Briefly, the duodenal biopsy global pattern of gene expression was determined using TruSeq mRNAseq library preparation and the Illumina platform.12 Genome-wide DNA methylation was profiled using the Illumina Infinium MethylationEPIC BeadChip platform (Illumina, Cambridge, UK; WG-317).13 Signed weighted gene coexpression network analysis (WGCNA) was implemented to identify modules of coexpressed genes.14 For each module in WGCNA, the first principal component, referred to as the eigengene, summarizes and represents the expression profiles of all the genes in a module. Candidate modules were identified based on the correlations between their respective module eigengenes and the phenotypic traits.

Biomarkers

Circulating, urine, and fecal biomarkers were measured at 9 months using commercial assays (Supplementary Methods). For AKU cases that underwent endoscopy, the presence of giardia in a duodenal aspirate (n = 50) was determined (TaqMan Assay), and stool (n = 47) was collected to calculate fecal energy loss (cal/g) using bomb calorimetry.15

Statistical Analysis

SEEM is reported as per the STROBE statement for observational cohort studies. The SEEM birth cohort study was designed to replicate the birth cohort study of 380 children conducted at AKU from 2013 to 2015 that identified EED biomarkers including IGF-1 and ferritin associated with linear growth rate at 18 months.16 Based on these findings, we planned to enroll 350 malnourished cases (WHZ < -2) and 50 well-nourished controls (WHZ > 0).6 In SEEM, 250 children with complete biomarker data at 9 months of age and growth data at 24 months of age were included in the final predictive model development, which provided 90% power to detect a slope of 0.22 for HAZ with 5% type I error. For the gene expression analysis, we planned to enroll 30 Cincinnati well-nourished controls and 50 malnourished children with EED from the SEEM cohort to provide 90% power to detect a 6-fold difference in duodenal IFNG and APOA1 gene expression with 5% type I error.17 Data were summarized descriptively as median (25th, 75th percentile) for continuous variables and frequency and percentage for categorical variables. Differences between the groups were evaluated using Wilcoxon rank sum test for independent continuous variables, and with chi-square test for categorical variables. The overall cohort with complete biomarker and growth data (n = 250) was randomly divided into independent training and validation groups with a 2:1 ratio. Model building was done using the training dataset, whereas the validation dataset was used to test the model performance. Conditional random forests (CRFs) analysis was performed using the training dataset to evaluate the relative importance of risk factors and log-transformed biomarkers while accounting for their correlations with a threshold of ≥ 0.5. The top predictors from CRF were used to develop the growth prediction models using linear regression. Statistical tests were conducted with 2-sided alpha level of .05. All data analyses were performed using the statistical packages SAS 9.4 (SAS Institute; Cary, NC) and R 4.0 (www.r-project.org).

Data availability. Data have been deposited in GEO under accession number GSE159495 (mRNAseq) and GSE157914 (methylation array chip).

Results

Participants

The SEEM-AKU birth cohort included 365 malnourished cases and 51 controls with adequate growth (Table 1, Supplementary Figure 1, and Supplementary Table 1) followed up to 24 months of age in Matari, Pakistan. Positive correlations (r > 0.4; P < .001) for biomarkers measured at 9 months of age for the overall cohort were noted between IGF-1 and leptin, CRP and AGP, and tumor necrosis factor α and IFNγ (Supplementary Figure 2). SEEM-AKU controls exhibited higher levels of urine creatinine, blood prealbumin, IGF1, GLP2, and leptin, and significantly reduced levels of urine Claudin15 and blood ferritin (Supplementary Table 1), in comparison with the malnourished cases. In this study, 189/365 participants with ongoing wasting (WHZ < -2) received nutritional intervention from age 9–10 months through 12 months. This resulted in a modest improvement in WAZ (mean change of 0.263 ± standard deviation [SD] of 0.704; P < .05).
but the infants still exhibited severe underweight (mean WAZ < -3) and stunting (mean HAZ < -2.5). Participants with ongoing wasting (median HAZ -3.2, WAZ -2.9, and WHZ of -2.2) were offered endoscopic evaluation (n = 63) around 20 months of age, and 1 research duodenal biopsy was obtained from each of the 52 for molecular profiling. Each had characteristic EED histologic features with severity scoring completed10 (Supplementary Table 2). We lacked indications to perform endoscopy on adequately growing local Matiari children, and, therefore, included 25 children with gastrointestinal symptoms but normal endoscopic findings, and 17 celiac cases, from Cincinnati as healthy and disease controls (Table 1). Supplementary Figure 1 illustrates the cases and controls for the

<table>
<thead>
<tr>
<th>Table 1. Clinical and Demographic Characteristics.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Female sex</td>
</tr>
<tr>
<td>Ethnicity (South-Asian)</td>
</tr>
<tr>
<td>Nutritional intervention</td>
</tr>
<tr>
<td>Age at entry (mo)</td>
</tr>
<tr>
<td>HAZ at entry</td>
</tr>
<tr>
<td>WAZ at entry</td>
</tr>
<tr>
<td>WHZ at entry</td>
</tr>
<tr>
<td>Biomarkers 9 mo of age*</td>
</tr>
<tr>
<td>Urine creatinine (μmol/L)</td>
</tr>
<tr>
<td>CRP (mg/dL)</td>
</tr>
<tr>
<td>Ferritin (ng/mL)</td>
</tr>
<tr>
<td>Hemoglobin (g/L)</td>
</tr>
<tr>
<td>IGF1 (ng/mL)</td>
</tr>
<tr>
<td>Prealbumin (mg/dL)</td>
</tr>
<tr>
<td>AGP (mg/dL)</td>
</tr>
<tr>
<td>Urine Claudin15 (ng/mL)</td>
</tr>
<tr>
<td>GLP2 (pg/mL)</td>
</tr>
<tr>
<td>Leptin (pg/mL)</td>
</tr>
<tr>
<td>TNF-α (pg/mL)</td>
</tr>
<tr>
<td>IFN-γ (pg/mL)</td>
</tr>
<tr>
<td>At the time of endoscopy</td>
</tr>
<tr>
<td>Age (y)</td>
</tr>
<tr>
<td>HAZ</td>
</tr>
<tr>
<td>WAZ</td>
</tr>
<tr>
<td>WHZ</td>
</tr>
<tr>
<td>24 mo anthropometrics</td>
</tr>
<tr>
<td>HAZ</td>
</tr>
<tr>
<td>WAZ</td>
</tr>
<tr>
<td>WHZ</td>
</tr>
</tbody>
</table>

NOTE. Data are shown as n (%) or median (25th,75th).
AGP, Alpha-1 Acid Glycoprotein; GLP2, Glucagon Like Peptide 2; TNF, tumor necrosis factor.
*Biomarkers measured at 9 mo were measured in blood unless indicated elsewhere.
Table 2. Models for HAZ, WAZ, and WHZ at 24 Mo of Age.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Estimate (SE)</th>
<th>P-value</th>
<th>Estimate (SE)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>-1.965 (-2.571, -1.359)</td>
<td>&lt;.001</td>
<td>-2.152 (-3.18, -1.125)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>HAZ at entry</td>
<td>0.519 (0.372, 0.667)</td>
<td>&lt;.001</td>
<td>0.489 (0.241, 0.736)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>ln(IGF1)</td>
<td>0.278 (0.134, 0.422)</td>
<td>&lt;.001</td>
<td>0.411 (0.206, 0.615)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>ln(Ferritin)</td>
<td>-0.120 (-0.217, -0.024)</td>
<td>.015</td>
<td>-0.216 (-0.429, -0.003)</td>
<td>.047</td>
</tr>
</tbody>
</table>

RMSE: 0.87, $R^2$: 31% (19%, 42%), Adjusted $R^2$: 29% (14%, 45%)

RMSE: 1.08, $R^2$: 35% (23%, 46%), Adjusted $R^2$: 32% (17%, 48%)
Table 2. Continued

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Estimate</th>
<th>P-value</th>
<th>Estimate</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>-2.701 (-3.656, -1.745)</td>
<td>&lt;.001</td>
<td>-4.246 (-5.59, -2.901)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>WAZ at entry</td>
<td>0.469 (0.322, 0.615)</td>
<td>&lt;.001</td>
<td>0.408 (0.179, 0.638)</td>
<td>.001</td>
</tr>
<tr>
<td>ln(IGF1)</td>
<td>0.247 (0.072, 0.422)</td>
<td>.006</td>
<td>0.150 (-0.075, 0.374)</td>
<td>.189</td>
</tr>
<tr>
<td>ln(Leptin)</td>
<td>0.134 (-0.073, 0.340)</td>
<td>.204</td>
<td>0.460 (0.168, 0.752)</td>
<td>.002</td>
</tr>
</tbody>
</table>

RMSE: 0.92, \(R^2\): 26% (15%, 37%),
Adjusted \(R^2\): 25% (10%, 40%)

RMSE: 1.03, \(R^2\): 30% (19%, 42%),
Adjusted \(R^2\): 28% (13%, 43%)
Table 2. Continued

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Estimate</th>
<th>P-value</th>
<th>Parameter</th>
<th>Estimate</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>-2.674 (-3.675, -1.674)</td>
<td>&lt;.001</td>
<td>Intercept</td>
<td>-2.710 (-3.974, -1.445)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>WHZ at entry</td>
<td>0.258 (0.114, 0.402)</td>
<td>.001</td>
<td>WHZ at entry</td>
<td>0.179 (-0.034, 0.392)</td>
<td>.098</td>
</tr>
<tr>
<td>ln(Leptin)</td>
<td>0.362 (0.173, 0.551)</td>
<td>&lt;.001</td>
<td>ln(Leptin)</td>
<td>0.326 (0.089, 0.563)</td>
<td>.008</td>
</tr>
<tr>
<td>ln(urine Claudin15)</td>
<td>-0.148 (-0.348, 0.053)</td>
<td>.148</td>
<td>ln(urine Claudin15)</td>
<td>0.088 (-0.176, 0.353)</td>
<td>.509</td>
</tr>
</tbody>
</table>

RMSE: 0.98, $R^2$: 15% (6%, 25%),
Adjusted $R^2$: 14% (1%, 27%)

RMSE: 0.97, $R^2$: 11% (2%, 19%),
Adjusted $R^2$: 7% (-3%, 18%)

**24 months WHZ**

**NOTE.** Estimates and $R^2$ are given with 95% confidence intervals.
RMSE, xxx.

*Graphs show the variable importance plots obtained with CRF for HAZ at 24 mo, WAZ at 24 mo, and WHZ at 24 mo.*

*Blood IGF1, ferritin and leptin biomarkers and urine Claudin15 were obtained at 9 mo, values were analyzed using natural log transformation (ln).*
molecular duodenal biopsy analysis, and for the biomarker growth model analysis.

Factors Associated With Growth at 24 Months of Age

We used available clinical data and biomarkers measured at 9 months of age to predict length/height (HAZ) and weight (WAZ and WHZ) at 24 months of age. Subjects with complete biomarker and growth data (n = 250) were randomly divided into independent training (n = 166) and validation (n = 84) groups (Supplementary Table 3). Model building was performed using the training dataset, and performance was tested on the validation subset. CRFs were used to prioritize factors to test in linear regression models, with adjusted $R^2$ used to test for overfitting (Table 2, Supplementary Table 4). For the continuous growth measures at 24 months (i.e., HAZ, WAZ, and WHZ as the primary responses), we presented $R^2$, adjusted $R^2$, and root mean square error as the primary model fitting measure. Higher HAZ around birth, and higher IGF1 and lower ferritin at 9 months, predicted higher HAZ at 24 months (adjusted $R^2$ of 29% in the training and 32% in the validation groups; Table 2). A scatter plot for HAZ at 24 months vs IGF at 9 months is shown in Supplementary Figure 3A (Spearman $rho = 0.305; P < .001$). Higher WAZ around birth and higher IGF1 and leptin at 9 months predicted higher WAZ at 24 months (adjusted $R^2$ of 25% in the training and 28% in the validation groups). A scatter plot for WAZ at 9 months vs IGF at 9 months is shown in Supplementary Figure 3B (Spearman $r = 0.356; P < .001$). This may imply that IGF-1 is to some extent a surrogate marker of nutritional status. The CRF prioritized WHZ around birth, leptin and urine claudin15 for WHZ at 24 months. However, these factors accounted for a small amount of the variation in WHZ at 24 months (adjusted $R^2$ of 14% in the training and 7% in the validation groups). Scatterplots of predicted vs observed values in the validation cohort for all the models built on the basis of data from the discovery cohort are shown in Supplementary Figure 3C. In agreement with our prior report, these data replicated circulating IGF-1 and ferritin as biomarkers to identify infants at risk for stunting (lower HAZ). However, although circulating leptin was strongly associated with wasting (lower WHZ), the multivariable model including leptin did not explain enough of the variation in weight gain to provide clinical utility. We, therefore, next tested whether the mucosal transcriptome would reveal novel immune and metabolic functions linked to wasting (lower WHZ).

The EED Intestinal Transcriptome and Pathways

We first defined the EED transcriptome in the affected duodenum. This included 1,262 genes (Figure 1, Supplementary Dataset 1) differentially expressed (FDR < 0.05 and fold change $\geq 1.5$) in a training group of 31 SEEM participants with EED vs 21 healthy North American controls (Ctl; Supplementary Table 5). These differentially expressed genes were validated in an independent group of 21 EED and 4 Ctl (Figure 1, Supplementary Dataset 1).

Figure 1A highlights the most differentially expressed genes, including up-regulation of antimicrobial DUOX2, LCN2, and IFNG, and down-regulation of digestion and metabolic genes PPARCIA, MMP28, LIPF, and SI. Unsupervised hierarchal clustering using the EED transcriptome demonstrated that all Ctl and 49/52 EED from both the training and independent validation subsets clustered together (Supplementary Figure 4; chi squares on the validation set; $P = 2.1E-5$). Similarly, principal component analysis to view participants’ separation using the EED gene list showed that Ctl separated from EED in the training but also in the independent validation cohorts (Figure 1B). Functional enrichment analysis of the 481 down-regulated EED genes identified suppressed epithelial transporters and channels ($P = 9.06E-10$), oxidoreductases and aldo-keto reductases ($P = 4.68E-09$), lipid metabolism ($P = 2.83E-11$), genes localized to microvillus and brush border (P = 3.06E-07), and metallothioneins (metal-binding proteins) with antioxidant function ($P = 5.50E-08$). Up-regulated enriched EED pathways included immune activation ($P = 7.33E-98$), response to external biotic stimulus ($P = 7.36E-76$), cytokine ($P = 7.80E-35$) and interferon ($P = 2.25E-22$) signaling, alpha beta ($P = 5.02E-77$) and gamma delta ($P = 3.09E-69$) T cells, and natural killer cells ($P = 9.23E-64$) (Figure 1C and D, Supplementary Dataset 1).

Similarities and Differences Between EED and Celiac Disease

Impaired growth, increased intestinal permeability, and T-cell–mediated enteropathy are shared features between celiac disease and EED,4 and we, therefore, included 17 celiac cases as disease controls. Representative histology for the healthy controls, celiac disease, and EED cases is shown in Figure 2A. Histology features used to define EED severity22 included villus blunting, intraepithelial lymphocytes, and Paneth cell depletion (Supplementary Table 2). The mean (SD) histology score of the EED cases was 5.7 (2.7), whereas the mean (SD) score for the celiac cases was 8.3 (4). In comparison to celiac disease, the EED cases demonstrated less pronounced intraepithelial lymphocytes and villous blunting, and more pronounced Paneth cell depletion (Supplementary Figure 5).

The celiac transcriptome included 718 genes (Figure 2, Supplementary Dataset 1) differentially expressed (FDR < 0.05 and fold change $\geq 1.5$) between 17 celiac cases and 25 Ctl. A Venn diagram (Figure 2B, Supplementary Dataset 1) indicates the overlap between EED and celiac signatures, whereas the heat map in Figure 2C illustrates the expression of the core EED genes across EED, celiac, and controls. The bacterial sensor DUOX2 and its adaptor DUOX2A, anti-viral defense genes (IFITM family), lipocalin-2 (LCN2), and several CCL chemokines were more specifically up-regulated in EED, whereas IFNG was up-regulated in both disorders. Shared down-regulated genes included the bile-acid transporter SLC10A2, carbohydrate (SI), lipid (APOA1), and retinol metabolic genes, whereas reduction of genes linked to detoxification (ALDH3A1), metal binding (metallothioneins family), and the aldo-keto reductase (AKR1C)
family were specific to EED. Enrichment analyses are shown in Figure 2D and E, highlighting shared signals for up-regulation of alpha-beta and gamma-delta T lymphocytes, and cell cycle and mitosis. More unique enrichments for EED included activation of innate responses to microbes, and cell adhesion. Shared down-regulated signals included genes linked with brush border functions, and lipid and retinol metabolism, whereas a more unique EED signal was linked with suppression of detoxification and aldo-keto reduced nicotinamide adenine dinucleotide phosphate reduction functions. Consistent with this, a greater level of LCN2 and DUOX2 protein staining (per stained surface area) was detected in duodenal biopsy specimens from EED subjects vs controls (Figure 2F and G, Supplementary Figure 6). Although there was some LCN2 stain detected also in celiac disease, DUOX2 staining was specific to the EED cases, and no LCN2 and DUOX2 was detected in controls. GZMB was observed in mononuclear inflammatory cells present in the lamina propria, and EED samples exhibited a higher number of granzyme-positive cells when compared with both celiac disease cases and controls (Supplementary Figure 6).

Variation in DNAm Associated With EED Gene Expression

Epigenetic mechanisms including DNA methylation (DNAm) mediate environmental influences on gene expression. Evidence in animal models and in humans suggests that maternal factors influence the offspring’s DNA methylation and thereby traits including postnatal growth. We, therefore, analyzed genome-wide DNA methylation (DNAm) of EED and control duodenal biopsy specimens.

**Figure 1.** The EED intestinal transcriptome and enriched biologic pathways. The core EED transcriptome was comprised of 1,262 genes (481 down- and 781 up-regulated) differentially expressed between 31 AKU-EED malnourished cases and 21 Cincinnati well-nourished controls in the training set (FDR < 0.05 and fold change [FC] ≥ 1.5 using bulk RNASeq of duodenal RNA) and assessed in an independent validation set of 21 EED and 4 Ctl. Unsupervised hierarchical clustering is visualized as a heatmap in (A) demonstrating the averaged normalized expression in AKU-EED malnourished cases and Cincinnati well-nourished controls in the training and validation groups for the top differentially expressed genes (more detailed heatmap in Supplementary Figure 4). (B) Principal component analysis (PCA) using the 1,262 EED genes transcriptome (determined only using the training subset) showing separation of the AKU-EED malnourished cases and the well-nourished controls from Cincinnati in both the training and validation groups on the PC1 axis that explains 38% of the total variance in gene expression. Functional enrichment analyses of the 781 up- (C) and 481 down-regulated (D) genes between AKU-EED malnourished cases and Cincinnati well-nourished controls was performed using ToppGene/ToppCluster and was visualized using Cytoscape.
specimens. Principal component analysis showed separation between EED and controls (Supplementary Figure 7). We identified 31,500 (between 31 EED vs 20 Ctl) and 9,102 (between 33 EED vs 9 Ctl) differentially methylated regions (DMRs) with FDR ≤ 0.01 (Supplementary Dataset 2), which when overlapped resulted in EED DMRs linked to 5,507 protein coding genes in both comparisons. A Manhattan plot (Figure 3A) illustrated the most significant findings linked with EED. Those included hyper-methylation in regions near genes involved in gene transcription (HOXA/HOXB), wound healing (TNXB), and epithelial adhesion (SERPINB5). Hypomethylated DMR included TSPAN32, located in the Beckwith-Wiedemann overgrowth imprinted gene domain, the transcription factor RUNX3 involved in chromatin modifications, differentiation, and proliferation, and the anti-viral IFITM gene family. We then defined regulatory DMR (rDMR) that spanned genes also differentially expressed in EED (Figure 3B). Down-regulated genes were enriched for differential methylation (47%; 225/481) in comparison with other expressed genes (34%; 4,539/13,464; chi-square $P < .0001$). We noted a trend toward enrichment of rDMR among the up-regulated genes (37%; 288/781 vs 34%; 4,539/13,464; chi-square $P = .07$). Figure 3C and D illustrates representative differentially methylated points within rDMR, focusing on up- and down-regulated genes that were previously shown to be expressed in human ileal epithelial cells$^{13}$ and in an epithelial single cell data set$^{22}$ (https://singlecell.broadinstitute.org). Increased gene expression in EED and hypo-methylation was noted in AOAH that hydrolyzes the acyl chain to detoxify LPS, CHI3L2, and PARP9 involved in interferon-mediated anti-viral responses. Decreased gene expression in EED coupled with hyper-methylation was noted in the mitochondria biogenesis and lipid metabolic regulator PPARGC1A, wound repair gene MMP28, and the tight junction CLDN15 gene that was increased in the urine of EED cases (Table 1).

**Gene Expression Modules Associated With Clinical Variables**

We applied WGCNA within EED cases aiming to capture networks linked with clinical factors and biomarkers and identified 7 modules that were linked (6 with $P < .05$ and the cyan model with $P = .08$) with EED diagnosis (Figure 4A). The complete 13-module WGCNA heat map and gene lists including modules hub genes (top 10% with highest gene expression significance) are in Supplementary Figure 8 and Supplementary Dataset 3. The red and green modules showed the strongest positive correlation with EED diagnosis, followed by the salmon, black, and cyan modules. Those modules show enrichment for innate and adaptive immune responses, whereas the black and salmon modules were also enriched for stem cells and cell proliferation (Figure 4B). The presence of giardia (detected in 32/50 available duodenal aspirates) was negatively correlated with these inflammatory modules (Figure 4A). In contrast, the brown and pink modules showed negative associations with EED diagnosis. Those modules were linked with metabolism of amino acids and lipids, oxidation reduction, and weight (WHZ) at study entry. Modules enriched for lymphocyte and monocyte/macrophage activation and proliferation were associated with EED severity as determined using histology scoring, and more specifically with intraepithelial lymphocytes, villous blunting, and Paneth cell depletion (Figure 4A). Remarkably, the salmon module linked to lymphocyte and monocyte/macrophage proliferation and stem cell function was specifically correlated with fecal energy loss detected using bomb calorimetry, and WHZ (wasting) both at study entry and at the time of biopsy (Figure 4, Supplementary Figure 8). The black module also showed significant association with WHZ (wasting). Hub genes from the brown and pink modules showed significant enrichment for genes that were also differentially methylated (Supplementary Dataset 3; 47% [103/221] for brown and 66% [21/32] for pink modules vs 34%; 4,539/13,464; chi-square $P < .03$). Consistent with this, the top 15 hub genes that are also differently methylated from the pink, brown, and salmon modules and their associated pathways emphasize likely epigenetic regulation of digestive (butyrate/butanoate, tryptophan, lipid, and amino acid metabolism) and adaptive immune networks, fecal energy loss, and wasting (Figure 4C and D). Interestingly, leptin also correlated with the duodenal pink ($r = .027; P = .05$) and magenta ($r = -.044; P < .001$; Supplementary Figure 8) coexpression gene modules encoding cellular metabolic functions. Typical speciments.
Discussion

SEEM Pakistan is a unique birth cohort that followed 416 at-risk children with varying degrees of growth impairment from birth to 24 months of age. Epigenetic and gene expression assays in the affected small intestine defined pathogenic mechanisms in children with wasting resistant to nutritional intervention. Coexpression module
analysis identified associations between genes encoding lymphocyte and monocyte/macrophage proliferation and stem cell function and key histologic features including intraepithelial lymphocytes, villous blunting, and Paneth cell depletion, in conjunction with fecal energy loss and wasting. Modules enriched for immune cell proliferation and metabolic functions demonstrated a differential epigenetic signal, which correlated with wasting (WHZ) around birth and at the time of biopsy. Infants with higher circulating IGFI, and lower ferritin, at 9 months were less likely to be stunted at 24 months, providing external replication of the results from our previous EED birth cohort16 and another recent EED study from Bangladesh.5 Adjusted R² of 32% and 28% for HAZ and WAZ, respectively, in our validation set indicated that the variations in responses can be explained fairly well, which may be useful in clinical practice and future research studies to identify children at greatest risk for stunting and associated future neurocognitive deficits. Here we further implicate leptin, previously shown to predict mortality in severely malnourished children,19 as a biomarker for future weight gain in a more stable population. Leptin measured at 9 months was associated with both duodenal expression of metabolic and stem cell renewal genes around 20 months, and the degree of wasting at 24 months. Collectively, these data define molecular pathways and biomarkers of EED pathogenesis, outcome, and severity.

We focused on celiac disease as a highly relevant enteropathy disease control group.10 Although there was substantial overlap at the molecular level between celiac and EED, we also emphasize EED-specific genes and pathways. These include up-regulation of an innate antimicrobial DUOX2 and LCN2 gene signature coupled with reduction of metallothioneins (MT family) that buffer against toxic metals, and aldo-keto nicotinamide adenine dinucleotide phosphate–dependent reduction genes (AKR1C family) involved in detoxification of environmental compounds. Those features widely overlap with the intestinal Crohn’s disease transcriptome.17,18 suggesting similar pathogenic mechanisms involving altered gut microbiota.5 In fact, the antimicrobial gene signature detected in SEEM is quite consistent with the recent report of duodenal microbiota, and host defense proteins, associated with stunting in children in Bangladesh and Zambia.19 Similarly, genes linked with cell cycling were linked with more severe enteropathy and histologic features in the Zambia cohort as observed in our cohort.20 Importantly, the specificity of the antimicrobial DUOX2 staining can potentially be used to differentiate between celiac disease and EED that require different therapeutic approaches, but further studies in the undernourished areas should further confirm its use as a discriminatory biomarker between those enteropathies. Collectively these data support the potential for microbiome-directed therapy to improve growth in EED. Microbiome-directed complementary feeding approaches are an active field of research.5,25

Gene coexpression modules regulating immune and metabolic functions in EED were linked to histologic severity, fecal energy loss, and wasting, with data supporting epigenetic regulation. Features of the EED transcriptome indicate a maladaptive gut inflammatory response, supporting results from a randomized controlled trial in Kenyan children with severe acute malnutrition in which treatment with the anti-inflammatory medication mesalazine was well-tolerated and produced modest reductions in several inflammatory markers vs placebo.26 We also observed suppression of metabolic pathways (part of the brown coexpression module; Figure 4C) with reduced butyrate, tryptophan, sphingolipid, and lipid metabolism, which were linked with wasting (WHZ). Similarly, low plasma tryptophan was recently associated with infections, chronic immune activation, and stunting.27 Interestingly, we observed that the presence of giardia significantly attenuated the inflammatory coexpression modules and may, therefore, play a role in the decreased response to vaccination noted in children with EED.28 This fascinating finding aligns with recent findings that showed reduced response to vaccination during helminth colonization in an animal model.29

Development, aging, diet, and gut microbes directly influence DNAm in the intestine. Promoting better nutrition and the gut microbial health through the lens of optimizing intestinal DNAm could inform therapies for EED that surmount its persistence in children and adults despite aggressive nutritional, pharmacological, and water, sanitation, and hygiene interventions and even immigration from low- to high-income countries. Our findings suggest that intestinal DNAm may provide a therapeutic target to reverse EED in children. Anthropometrics within the first month of life were strong predictors of growth at 24 months and such findings were consistent with that from the birth cohort studies in Bangladesh.5,26,30 Interestingly, wasting (WHZ) around the time of birth also showed significant association with several immune and metabolic duodenal gene coexpression modules measured around 20 months, some of which were also enriched for epigenetic DNAm modifications. Prenatal and perinatal environmental exposures31 that were not part of the current dataset may influence tissue DNAm,32 and thereby traits expressed later in life including growth and inflammatory responses.13 Our findings linking early wasting to genes that are differentially expressed and methylated align with those previous observations and early determinates. Supplementation with folate—an essential methyl donor nutrient—is an effective adjunct therapy for persistent diarrhea in children with malnutrition.33 Further, intestinal stem cell–specific deletion of DNA methyltransferase 134 or a diet deficient in folate and choline35 recapitulates several features of EED in mice. Further, the abundance of differentially methylated genes detected in our study suggests fecal intestinal epithelial cell methylation screens might be developed for EED to provide a noninvasive stool-based approach for detection and monitoring of EED, as is currently done for colorectal cancer. Additionally, healthy gut microbiota provides an endogenous source of methyl donor nutrient producers and microbiome-directed complementary feeding approaches are an active field of research.25 Collectively data suggest that interventions targeting epigenetic drivers...

Environmental Enteric Dysfunction Pathogenesis 13
of the core regulatory genes at an early time point, even prenatally, may be necessary to reverse mucosal injury and improve energy balance in EED.

Our work has several strengths because we investigated EED in a large birth cohort in Matiari, Pakistan, where children are at risk for undernutrition, and analyzed duodenal biopsy specimens from participants with wasting unresponsive to nutritional intervention defined in a prospective manner. The prospective study design afforded a unique opportunity to define the molecular basis for EED.
pathogenesis using state-of-the-art whole-genome methylome and transcriptome analyses of the affected gut and to characterize predictive biomarkers in independent training and validation groups. Limitations included the need to use an older group of North American healthy controls for the molecular comparisons due to lack of indications to perform endoscopy on adequately growing local Matiari controls and the use of bulk biopsies rather than single-cell separation, which would have been challenging in the setting of EED case sampling. We also lacked data for gestational age or birth weight and microbial data. Ongoing data generation and analysis, including future studies using more advanced technologies and biopsies from similar age and ethnic background may overcome some of these challenges.

Conclusions

We defined a core EED intestinal transcriptome, emphasizing unique antimicrobial immune responses and detoxification functions relative to celiac disease. Specific gene coexpression modules regulating immune and metabolic functions in EED were linked to histologic severity, fecal energy loss, and wasting, with data supporting epigenetic regulation. Random forest and linear regression models, which accounted for initial weight and length, identified circulating IGF-1, ferritin, and leptin as informative biomarkers for future growth. Collectively, these data will inform enrollment of infants at greatest risk for future wasting and stunting into interventional trials of more targeted therapies in the future.

Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org, and at https://doi.org/10.1053/j.gastro.2021.01.221.

References


13. Howell KJ, Kraiczy J, Nayak KM, et al. DNA methylation and transcription patterns in intestinal epithelial cells from pediatric patients with inflammatory bowel diseases...
16 Haberman et al

Gastroenterology Vol. No.

differentiate disease subtypes and associate with outcome. Gastroenterology 2018;154:585–598.


Received November 16, 2020. Accepted January 22, 2021.

Correspondence
Address correspondence to: Lee A Denson, MD, Division of Pediatric Gastroenterology, Hepatology, & Nutrition, Cincinnati Children's Hospital Medical Center; MLC 2010, 3333 Burnet Avenue, Cincinnati, Ohio 45229. e-mail: Lee.denson@cchmc.org; fax: (513) 636-558.

Acknowledgments
The authors gratefully acknowledge Anita Zaidi, Yi Wu He, Christopher Karp, Chris Damman, Phil Tar, and Donna M. Denno for their valuable suggestions and discussion. We also thank the field staff, the data management unit of AKU, and the families and children who participated in the study. We also thank Erin Bonkowski and Elizabeth Maier for technical support.

CRediT Authorship Contributions
Yael Haberman, MD, PhD (Conceptualization: Lead; Data curation: Lead; Formal analysis: Lead; Methodology: Lead; Writing – original draft: Lead; Writing – review & editing: Lead)

Najeeha T. Iqbal, PhD (Conceptualization: Lead; Data curation: Lead; Formal analysis: Lead; Funding acquisition: Lead; Investigation: Lead; Methodology: Lead; Writing – review & editing: Lead)

Sudhir Ghandikota, MS (Data curation: Equal; Formal analysis: Lead; Methodology: Lead; Writing – review & editing: Equal)

Indika Mallawarachchis, MS (Data curation: Equal; Formal analysis: Lead; Methodology: Lead; Writing – review & editing: Equal)

Philip J. Dexheimer, MS (Data curation: Equal; Formal analysis: Lead; Methodology: Lead; Writing – review & editing: Equal)

Najeeb Rahman, MS (Data curation: Equal; Formal analysis: Lead; Methodology: Lead; Writing – review & editing: Equal)

Rotem Hadar, MS (Formal analysis: Lead; Methodology: Equal; Writing – review & editing: Equal)

Zubair Ahmad, MBBS (Data curation: Equal; Formal analysis: Equal; Methodology: Lead; Resources: Lead; Writing – review & editing: Equal)

Romana Idress, MBBS (Data curation: Equal; Formal analysis: Equal; Writing – review & editing: Equal)

Junaid Iqbal, PhD (Data curation: Equal; Formal analysis: Supporting; Writing – review & editing: Equal)

Sheraz Ahmed, MS (Data curation: Equal; Formal analysis: Supporting; Writing – review & editing: Equal)

Aneeta Hotwani, MS (Data curation: Equal; Formal analysis: Supporting; Writing – review & editing: Equal)

Fayyaz Umran, MBBS (Data curation: Equal; Formal analysis: Supporting; Writing – review & editing: Equal)

Lubaina Ehsan, MD (Data curation: Equal; Formal analysis: Supporting; Writing – review & editing: Equal)
Environmental Enteric Dysfunction Pathogenesis

Conflicts of interest
The authors disclose no conflicts.

Funding
This work was supported by the Bill and Melinda Gates Foundation (OPP1144149 and OPP1138727), NIDDK P30 DK078392 (Integrative Morphology and Gene Expression Cores), and FIC K43TW010697 (Microbiota, Inflammation and Environmental Enteric Dysfunction [MiEED]). Y.H. is also supported in part by the Helmsley Charitable Trust, and the ERC (758313). The Bill and Melinda Gates Foundation and the National Institutes of Health funded the cohort and data generation. The funding sources did not have a role in writing the manuscript or the decision to submit it for publication, did not have a role in data collection, analysis, or interpretation, trial design, patient recruitment, or any aspect pertinent to the study.